{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T21:52:21Z","timestamp":1788731541644,"version":"build-2803163510"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T00:00:00Z","timestamp":1744416000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T00:00:00Z","timestamp":1744416000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-96284-0","type":"journal-article","created":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T20:43:11Z","timestamp":1744490591000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Repurposing FDA-approved drugs and natural compounds to inhibit the RNA-dependent RNA polymerase domain of dengue virus 2 or dengue virus 3"],"prefix":"10.1038","volume":"15","author":[{"given":"Khadijeh","family":"Ahmadi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamid Reza","family":"Jahantigh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nahid","family":"Ahmadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Behzad","family":"Shahbazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,12]]},"reference":[{"key":"96284_CR1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s10096-018-3375-7","volume":"38","author":"S Sukhralia","year":"2019","unstructured":"Sukhralia, S. et al. From dengue to Zika: The wide spread of mosquito-borne arboviruses. Eur. J. Clin. Microbiol. Infect. Dis. 38, 3\u201314 (2019).","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"96284_CR2","doi-asserted-by":"publisher","first-page":"517","DOI":"10.2471\/BLT.16.182105","volume":"95","author":"H-H Chang","year":"2017","unstructured":"Chang, H.-H. et al. Systematic analysis of protein identity between Zika virus and other arthropod-borne viruses. Bull. World Health Organ. 95, 517 (2017).","journal-title":"Bull. World Health Organ."},{"key":"96284_CR3","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1111\/j.1751-2824.2012.01602.x","volume":"7","author":"G Anez","year":"2012","unstructured":"Anez, G., Chancey, C., Grinev, A. & Rios, M. Dengue virus and other arboviruses: A global view of risks. ISBT Sci. Ser. 7, 274\u2013282 (2012).","journal-title":"ISBT Sci. Ser."},{"key":"96284_CR4","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1089\/vbz.2020.2762","volume":"21","author":"J N\u00e4slund","year":"2021","unstructured":"N\u00e4slund, J. et al. Emerging mosquito-borne viruses linked to Aedes aegypti and Aedes albopictus: Global status and preventive strategies. Vector Borne Zoonotic Dis. 21, 731\u2013746 (2021).","journal-title":"Vector Borne Zoonotic Dis."},{"key":"96284_CR5","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/S1995-7645(14)60016-X","volume":"7","author":"P Chawla","year":"2014","unstructured":"Chawla, P., Yadav, A. & Chawla, V. Clinical implications and treatment of dengue. Asian Pac. J. Trop. Med. 7, 169\u2013178 (2014).","journal-title":"Asian Pac. J. Trop. Med."},{"key":"96284_CR6","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.antiviral.2018.12.016","volume":"163","author":"SP Lim","year":"2019","unstructured":"Lim, S. P. Dengue drug discovery: Progress, challenges and outlook. Antivir. Res. 163, 156\u2013178 (2019).","journal-title":"Antivir. Res."},{"issue":"2","key":"96284_CR7","first-page":"016","volume":"2","author":"MK Sahu","year":"2023","unstructured":"Sahu, M. K. & Tiwari, S. P. A systemic review on recent outbreaks of dengue and newer US FDA approved drug. J. Infect. Dis. Virus Res. 2(2), 016 (2023).","journal-title":"J. Infect. Dis. Virus Res."},{"key":"96284_CR8","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1093\/cid\/civ949","volume":"62","author":"J Whitehorn","year":"2016","unstructured":"Whitehorn, J. et al. Lovastatin for the treatment of adult patients with dengue: A randomized, double-blind, placebo-controlled trial. Clin. Infect. Dis. 62, 468\u2013476 (2016).","journal-title":"Clin. Infect. Dis."},{"key":"96284_CR9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0087412","volume":"9","author":"M Martinez-Gutierrez","year":"2014","unstructured":"Martinez-Gutierrez, M., Correa-Londo\u00f1o, L. A., Castellanos, J. E., Gallego-G\u00f3mez, J. C. & Osorio, J. E. Lovastatin delays infection and increases survival rates in AG129 mice infected with dengue virus serotype 2. PLoS ONE 9, e87412 (2014).","journal-title":"PLoS ONE"},{"key":"96284_CR10","first-page":"0917","volume":"2009","author":"MM Alejandria","year":"2009","unstructured":"Alejandria, M. M. Dengue haemorrhagic fever or dengue shock syndrome in children. BMJ Clin. Evid. 2009, 0917 (2009).","journal-title":"BMJ Clin. Evid."},{"key":"96284_CR11","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/S0022-3476(97)70055-6","volume":"131","author":"S Tassniyom","year":"1997","unstructured":"Tassniyom, S., Vasanawathana, S., Dhiensiri, T., Nisalak, A. & Chirawatkul, A. Failure of carbazochrome sodium sulfonate (AC-17) to prevent dengue vascular permeability or shock: A randomized, controlled trial. J. Pediatr. 131, 525\u2013528 (1997).","journal-title":"J. Pediatr."},{"key":"96284_CR12","first-page":"1","volume":"2014","author":"F Zhang","year":"2014","unstructured":"Zhang, F. & Kramer, C. V. Corticosteroids for dengue infection. Cochrane Database Syst. Rev. 2014, 1\u201343 (2014).","journal-title":"Cochrane Database Syst. Rev."},{"key":"96284_CR13","first-page":"164","volume":"24","author":"MI Suliman","year":"2014","unstructured":"Suliman, M. I., Qayum, I. & Saeed, F. Randomized clinical trial of human interleukin-11 in dengue fever-associated thrombocytopenia. J. Coll. Physicians Surg. Pak. 24, 164\u2013168 (2014).","journal-title":"J. Coll. Physicians Surg. Pak."},{"key":"96284_CR14","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.cyto.2006.04.002","volume":"34","author":"JE Cardier","year":"2006","unstructured":"Cardier, J. E. et al. Relationship of thrombopoietin and interleukin-11 levels to thrombocytopenia associated with dengue disease. Cytokine 34, 155\u2013160 (2006).","journal-title":"Cytokine"},{"key":"96284_CR15","doi-asserted-by":"crossref","unstructured":"Pushpakom, S. Introduction and Historical Overview of Drug Repurposing Opportunities (2022).","DOI":"10.1039\/9781839163401-00001"},{"key":"96284_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/978-2-88971-239-7","volume-title":"Repurposed Drugs Targeting Cancer Signaling Pathways: Clinical Insights to Improve Oncologic Therapies","author":"AD Campos-Parra","year":"2021","unstructured":"Campos-Parra, A. D., P\u00e9rez-Plasencia, C., Padilla-Benavides, T. & L\u00f3pez-Urrutia, E. Repurposed Drugs Targeting Cancer Signaling Pathways: Clinical Insights to Improve Oncologic Therapies (Frontiers Media SA, 2021)."},{"key":"96284_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.605386","volume":"10","author":"M Montalvo-Casimiro","year":"2020","unstructured":"Montalvo-Casimiro, M. et al. Epidrug repurposing: Discovering new faces of old acquaintances in cancer therapy. Front. Oncol. 10, 605386 (2020).","journal-title":"Front. Oncol."},{"key":"96284_CR18","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.ejmech.2015.12.046","volume":"109","author":"F Benmansour","year":"2016","unstructured":"Benmansour, F. et al. Novel 2-phenyl-5-[(E)-2-(thiophen-2-yl) ethenyl]-1,3,4-oxadiazole and 3-phenyl-5-[(E)-2-(thiophen-2-yl) ethenyl]-1,2,4-oxadiazole derivatives as dengue virus inhibitors targeting NS5 polymerase. Eur. J. Med. Chem. 109, 146\u2013156 (2016).","journal-title":"Eur. J. Med. Chem."},{"key":"96284_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2022.105639","volume":"120","author":"W Qian","year":"2022","unstructured":"Qian, W. et al. Design, synthesis, discovery and SAR of the fused tricyclic derivatives of indoline and imidazolidinone against DENV replication and infection. Bioorg. Chem. 120, 105639 (2022).","journal-title":"Bioorg. Chem."},{"key":"96284_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2023.115416","volume":"256","author":"GP Sreekanth","year":"2023","unstructured":"Sreekanth, G. P. Perspectives on the current antiviral developments towards RNA-dependent RNA polymerase (RdRp) and methyltransferase (MTase) domains of dengue virus non-structural protein 5 (DENV-NS5). Eur. J. Med. Chem. 256, 115416 (2023).","journal-title":"Eur. J. Med. Chem."},{"key":"96284_CR21","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/j.ejmech.2016.10.007","volume":"125","author":"F Benmansour","year":"2017","unstructured":"Benmansour, F. et al. Discovery of novel dengue virus NS5 methyltransferase non-nucleoside inhibitors by fragment-based drug design. Eur. J. Med. Chem. 125, 865\u2013880 (2017).","journal-title":"Eur. J. Med. Chem."},{"key":"96284_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2020.115713","volume":"28","author":"JE Thames","year":"2020","unstructured":"Thames, J. E. et al. Synthesis and biological evaluation of novel flexible nucleoside analogues that inhibit flavivirus replication in vitro. Bioorg. Med. Chem. 28, 115713 (2020).","journal-title":"Bioorg. Med. Chem."},{"key":"96284_CR23","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.coviro.2014.08.006","volume":"9","author":"DD Boehr","year":"2014","unstructured":"Boehr, D. D., Liu, X. & Yang, X. Targeting structural dynamics of the RNA-dependent RNA polymerase for anti-viral strategies. Curr. Opin. Virol. 9, 194\u2013200 (2014).","journal-title":"Curr. Opin. Virol."},{"key":"96284_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2021.e06435","volume":"7","author":"MK Hasan","year":"2021","unstructured":"Hasan, M. K. et al. Structural analogues of existing anti-viral drugs inhibit SARS-CoV-2 RNA dependent RNA polymerase: A computational hierarchical investigation. Heliyon 7, e06435 (2021).","journal-title":"Heliyon"},{"key":"96284_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2021.113698","volume":"224","author":"IJ dos Santos Nascimento","year":"2021","unstructured":"dos Santos Nascimento, I. J., da Silva Santos-Junior, P. F., de Aquino, T. M., de Araujo-Junior, J. X. & da Silva-Junior, E. F. Insights on dengue and Zika NS5 RNA-dependent RNA polymerase (RdRp) inhibitors. Eur. J. Med. Chem. 224, 113698 (2021).","journal-title":"Eur. J. Med. Chem."},{"key":"96284_CR26","doi-asserted-by":"publisher","first-page":"155","DOI":"10.2217\/17460913.3.2.155","volume":"3","author":"R Bartenschlager","year":"2008","unstructured":"Bartenschlager, R. & Miller, S. Molecular aspects of dengue virus replication. Future Microbiol. 3, 155\u2013165 (2008).","journal-title":"Future Microbiol."},{"key":"96284_CR27","doi-asserted-by":"publisher","first-page":"4753","DOI":"10.1128\/JVI.02283-06","volume":"81","author":"TL Yap","year":"2007","unstructured":"Yap, T. L. et al. Crystal structure of the dengue virus RNA-dependent RNA polymerase catalytic domain at 1.85-angstrom resolution. J. Virol. 81, 4753\u20134765 (2007).","journal-title":"J. Virol."},{"key":"96284_CR28","volume-title":"An Introduction to Hydrogen Bonding","author":"GA Jeffrey","year":"1997","unstructured":"Jeffrey, G. A. An Introduction to Hydrogen Bonding (Oxford University Press, 1997)."},{"key":"96284_CR29","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/513481a","volume":"513","author":"J Baell","year":"2014","unstructured":"Baell, J. & Walters, M. A. Chemistry: Chemical con artists foil drug discovery. Nature 513, 481\u2013483 (2014).","journal-title":"Nature"},{"key":"96284_CR30","doi-asserted-by":"publisher","first-page":"638","DOI":"10.3390\/pharmaceutics11120638","volume":"11","author":"AB S\u00e1nchez","year":"2019","unstructured":"S\u00e1nchez, A. B., Calpena, A. C., Mallandrich, M. & Clares, B. Validation of an ex vivo permeation method for the intestinal permeability of different BCS drugs and its correlation with Caco-2 in vitro experiments. Pharmaceutics 11, 638 (2019).","journal-title":"Pharmaceutics"},{"key":"96284_CR31","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1002\/prot.340170408","volume":"17","author":"A Amadei","year":"1993","unstructured":"Amadei, A., Linssen, A. B. & Berendsen, H. J. Essential dynamics of proteins. Proteins Struct. Funct. Bioinform. 17, 412\u2013425 (1993).","journal-title":"Proteins Struct. Funct. Bioinform."},{"key":"96284_CR32","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/978-1-62703-658-0_11","volume-title":"Protein Dynamics: Methods and Protocols","author":"CC David","year":"2014","unstructured":"David, C. C. & Jacobs, D. J. Principal component analysis: A method for determining the essential dynamics of proteins. In Protein Dynamics: Methods and Protocols (ed. Livesay, D. R.) 193\u2013226 (Humana Press, 2014)."},{"key":"96284_CR33","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.ejmech.2019.05.010","volume":"176","author":"SN Dighe","year":"2019","unstructured":"Dighe, S. N., Dua, K., Chellappan, D. K., Katavic, P. L. & Collet, T. A. Recent update on anti-dengue drug discovery. Eur. J. Med. Chem. 176, 431\u2013455 (2019).","journal-title":"Eur. J. Med. Chem."},{"key":"96284_CR34","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1007\/s40265-016-0611-2","volume":"76","author":"ED Deeks","year":"2016","unstructured":"Deeks, E. D. Lumacaftor\/ivacaftor: A review in cystic fibrosis. Drugs 76, 1191\u20131201 (2016).","journal-title":"Drugs"},{"key":"96284_CR35","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/j.jcf.2020.11.007","volume":"20","author":"G Berkers","year":"2021","unstructured":"Berkers, G. et al. Lumacaftor\/ivacaftor in people with cystic fibrosis with an A455E\u2013CFTR mutation. J. Cyst. Fibros. 20, 761\u2013767 (2021).","journal-title":"J. Cyst. Fibros."},{"key":"96284_CR36","doi-asserted-by":"publisher","DOI":"10.5808\/gi.23035","volume":"21","author":"A Zeba","year":"2023","unstructured":"Zeba, A., Sekar, K. & Ganjiwale, A. M protein from dengue virus oligomerizes to pentameric channel protein: In silico analysis study. Genom. Inform. 21, e41 (2023).","journal-title":"Genom. Inform."},{"key":"96284_CR37","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1128\/mBio.03681-20","volume":"12","author":"CJ Day","year":"2021","unstructured":"Day, C. J. et al. Multidisciplinary approaches identify compounds that bind to human ACE2 or SARS-CoV-2 spike protein as candidates to block SARS-CoV-2-ACE2 receptor interactions. MBio 12, 10\u20131128 (2021).","journal-title":"MBio"},{"key":"96284_CR38","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1177\/1060028015573564","volume":"49","author":"JR White Jr","year":"2015","unstructured":"White, J. R. Jr. Empagliflozin, an SGLT2 inhibitor for the treatment of type 2 diabetes mellitus: A review of the evidence. Ann. Pharmacother. 49, 582\u2013598 (2015).","journal-title":"Ann. Pharmacother."},{"key":"96284_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12933-019-0816-2","volume":"18","author":"C Li","year":"2019","unstructured":"Li, C. et al. SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart. Cardiovasc. Diabetol. 18, 1\u201313 (2019).","journal-title":"Cardiovasc. Diabetol."},{"key":"96284_CR40","first-page":"384","volume":"22","author":"ZA Jigheh","year":"2019","unstructured":"Jigheh, Z. A. et al. Empagliflozin alleviates renal inflammation and oxidative stress in streptozotocin-induced diabetic rats partly by repressing HMGB1-TLR4 receptor axis. Iran. J. Basic Med. Sci. 22, 384 (2019).","journal-title":"Iran. J. Basic Med. Sci."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-96284-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-96284-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-96284-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T20:43:14Z","timestamp":1744490594000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-96284-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,12]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["96284"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-96284-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,12]]},"assertion":[{"value":"4 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"12698"}}